Effects of Low-Dose Paroxetine 7.5 MG on Weight and Sexual Function During Treatment of Vasomotor Symptoms Associated with Menopause

Two phase 3, randomized, placebo-controlled trials demonstrated that low-dose paroxetine 7.5 mg reduced the frequency and severity of vasomotor symptoms (VMS) associated with menopause and had a favorable tolerability profile. The impact of paroxetine 7.5 mg on body weight and sexual function was evaluated in a pooled analysis.

Download PDF